Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skyliv is a hepatoprotective liver support formulation developed and marketed by Skyways Healthcare. It is a multi-ingredient product containing silymarin, a mixture of flavonolignans extracted from milk thistle (Silybum marianum), alongside a complex of B-vitamins including Thiamine (B1), Riboflavine (B2), Pyridoxine (B6), Niacinamide (B3), D-Panthenol (B5), and Vitamin B12. Silymarin is recognized for its antioxidant, anti-inflammatory, and antifibrotic properties, which help stabilize hepatocyte membranes and promote liver cell regeneration by stimulating protein synthesis. The B-vitamin components act as essential cofactors in various hepatic metabolic pathways, supporting overall liver health and detoxification processes. Skyliv is typically used as a supplement or medication for the management of liver disorders and general hepatoprotection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Skyliv.